ArticleFrontiers in pharmacology2022

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.

Jing Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.